Wyeth Premarin Market-Share Rebates Challenged In Duramed Antitrust Suit
Executive Summary
Wyeth-Ayerst's Premarin market share-based rebates represent an antitrust violation, Duramed maintained in a lawsuit filed Sept. 5 in Cincinnati federal court.
You may also be interested in...
Cenestin Settlement: Barr Boosts Branded Business With Five Wyeth Products
Barr will add an oral contraceptive in development at Wyeth as part of an acquisition deal that settles Cenestin antitrust litigation
Cenestin Settlement: Barr Boosts Branded Business With Five Wyeth Products
Barr will add an oral contraceptive in development at Wyeth as part of an acquisition deal that settles Cenestin antitrust litigation
Wyeth Wants Premarin Petitions Excluded From Duramed Antitrust Suit
Wyeth-Ayerst's efforts to influence regulatory decisions about conjugated estrogens via citizens' petitions are an early focus of arguments in Duramed's antitrust suit against the company.